S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
NYSEAMERICAN:ISR

Isoray Stock Forecast, Price & News

$0.43
-0.02 (-5.21%)
(As of 12/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.43
$0.47
50-Day Range
N/A
52-Week Range
$0.37
$2.81
Volume
636,607 shs
Average Volume
5.06 million shs
Market Capitalization
$60.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.9
30 days | 90 days | 365 days | Advanced Chart
Receive ISR News and Ratings via Email

Sign-up to receive the latest news and ratings for Isoray and its competitors with MarketBeat's FREE daily newsletter.


Isoray logo

About Isoray

IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The firm focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.

Headlines

Isoray (NYSEAMERICAN:ISR) Issues Earnings Results
November 11, 2021 |  americanbankingnews.com
Isoray Announces First Quarter Fiscal 2022 Financial Results
November 10, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:ISR
Previous Symbol
NYSEMKT:ISR
Employees
53
Year Founded
N/A

Sales & Book Value

Annual Sales
$10.05 million
Book Value
$0.48 per share

Profitability

Net Income
$-3.39 million
Pretax Margin
-48.05%

Debt

Price-To-Earnings

Miscellaneous

Free Float
138,481,000
Market Cap
$60.67 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
12/01/2021
Fiscal Year End
6/30/2022

MarketRank

Overall MarketRank

1.91 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -












Isoray (NYSEAMERICAN:ISR) Frequently Asked Questions

Is Isoray a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Isoray in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Isoray stock.
View analyst ratings for Isoray
or view top-rated stocks.

How has Isoray's stock been impacted by Coronavirus (COVID-19)?

Isoray's stock was trading at $0.6706 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ISR stock has decreased by 35.8% and is now trading at $0.4307.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Isoray?

Isoray saw a decline in short interest in October. As of October 15th, there was short interest totaling 1,300,000 shares, a decline of 22.6% from the September 30th total of 1,680,000 shares. Based on an average trading volume of 704,700 shares, the short-interest ratio is currently 1.8 days. Currently, 0.9% of the company's shares are sold short.
View Isoray's Short Interest
.

How were Isoray's earnings last quarter?

Isoray, Inc. (NYSEAMERICAN:ISR) issued its earnings results on Wednesday, November, 10th. The healthcare company reported ($0.02) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.01) by $0.01. The healthcare company earned $2.56 million during the quarter, compared to the consensus estimate of $2.58 million. Isoray had a negative trailing twelve-month return on equity of 9.19% and a negative net margin of 48.05%.
View Isoray's earnings history
.

What price target have analysts set for ISR?

4 analysts have issued 1-year price objectives for Isoray's stock. Their forecasts range from $1.00 to $3.00. On average, they anticipate Isoray's share price to reach $1.84 in the next year. This suggests a possible upside of 326.6% from the stock's current price.
View analysts' price targets for Isoray
or view top-rated stocks among Wall Street analysts.

Who are Isoray's key executives?

Isoray's management team includes the following people:
  • Lori A. Woods, Chief Executive Officer & Director
  • Jennifer Streeter, Chief Operating Officer & VP-Human Resources
  • Mark J. Austin, Co-CFO, Secretary & Chief Accounting Officer
  • Jonathan R. Hunt, Co-Chief Financial Officer
  • William A. Cavanagh, Chief Research & Development Officer

What other stocks do shareholders of Isoray own?

What is Isoray's stock symbol?

Isoray trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ISR."

Who are Isoray's major shareholders?

Isoray's stock is owned by many different retail and institutional investors. Top institutional investors include Perkins Capital Management Inc. (1.09%), Renaissance Technologies LLC (0.84%), Marshall Wace LLP (0.03%) and UBS Group AG (0.03%). Company insiders that own Isoray stock include Jonathan Robert Hunt, Lori A Woods, Mark John Austin, Michael Krachon and Philip J Vitale.
View institutional ownership trends for Isoray
.

Which institutional investors are selling Isoray stock?

ISR stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Perkins Capital Management Inc..
View insider buying and selling activity for Isoray
or view top insider-selling stocks.

Which institutional investors are buying Isoray stock?

ISR stock was acquired by a variety of institutional investors in the last quarter, including Marshall Wace LLP, and UBS Group AG. Company insiders that have bought Isoray stock in the last two years include Jonathan Robert Hunt, Lori A Woods, Mark John Austin, Michael Krachon, and Philip J Vitale.
View insider buying and selling activity for Isoray
or or view top insider-buying stocks.

How do I buy shares of Isoray?

Shares of ISR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Isoray's stock price today?

One share of ISR stock can currently be purchased for approximately $0.43.

How much money does Isoray make?

Isoray has a market capitalization of $61.12 million and generates $10.05 million in revenue each year. The healthcare company earns $-3.39 million in net income (profit) each year or ($0.05) on an earnings per share basis.

How many employees does Isoray have?

Isoray employs 53 workers across the globe.

What is Isoray's official website?

The official website for Isoray is isoray.com.

Where are Isoray's headquarters?

How can I contact Isoray?

Isoray's mailing address is 350 Hills St Ste 106, RICHLAND, WA 99354-5511, United States. The healthcare company can be reached via phone at (509) 375-1202, via email at [email protected], or via fax at 509-267-3670.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.